Improve the Rational Design and Translation of Next Generation Small Molecules to Successfully Drug Highly Desirable, Yet Difficult to Reach "Undruggable" Targets
As the renaissance in small molecule drug discovery continues and with over 80% of the proteome waiting to be drugged, the inaugural Proteome- Targeted Drug Discovery Summit 2019 has been founded with the sole purpose to help biopharma drug developers and academic research institutes finally overcome the "undruggable" nature of hard to reach, yet immensely desirable proteome targets.
KEY Features of the Proteome- Targeted Drug Discovery Summit:
World-class speaker faculty from the likes of Amgen, AstraZeneca, Pfizer and Novartis
Curated learning journey from early discovery to clinical development
Critical strategic discussions and case studies focused on the current trends, challenges and opportunities of proteome drug discovery
Intimate networking with key decision-makers from large pharma, biotech and academia through high-quality discussions
"This meeting is set out to explore a particularly exciting area of drug discovery and given the excellent line-up I hope to gather interesting insights, feedback and new ideas that can ultimately move us closer to systematically drugging the undruggable"
Markus Muellner, CTO, PhoreMost Ltd
"I look forward to hear and discuss about novel approaches to well validated and highly desirable yet difficult or undruggable drug targets"
Xin Huang, Head of Structural Biology, Amgen
Conference Only (Industry Pricing): USD 2899.0,
Conference + 1 Workshop (Industry Pricing): USD 3299.0,
Conference + 2 Workshops (Industry Pricing): USD 3799.0,
Workshops each (Industry Pricing): USD 599.0,
Conference Only (Academic Pricing): USD 1999.0,
Conference + 1 Workshop (Academic Pricing): USD 2498.0,
Conference + 2 Workshops (Academic Pricing): USD 2997.0,
Workshops each (Academic Pricing): USD 499.0
Speakers: Alexander V. Statsyuk, University of Houston, Angela N. Koehler, Koch Institute for Integrative Cancer Research at MIT, Daniel Finley, Harvard Medical School, Daniel Nomura, University of California, Berkeley, David Millan, Foghorn Therapeutics, Eric S. Fischer, Dana-Farber Cancer Institute, Gerald Shipps, Pfizer, Gregory P. Way, Broad Institute, Haian Fu, Emory University School of Medicine, Jeffrey Iwig, Carmot Therapeutics, John S. Lazo, University of Virginia, Markus Muellner, PhoreMost Ltd, Matthew LaMarche, Novartis, Milka Kostic, Dana-Farber Cancer Institute, Nello Mainolfi, Kymera Therapeutics, Nicolas Thomä, Friedrich Miescher Institute for Biomedical Research, Roman C. Hillig, Bayer AG, Stephan Schürer, University of Miami, Stephanos Ioannidis, Forma Therapeutics, Xin Huang, Amgen, Paola Castaldi, AstraZeneca